Zai Lab Ltd
Company Profile
Business description
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Contact
899 Halei Road
Building B
Pudong
Shanghai201203
CHNT: +86 2161632588
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,784
Stocks News & Analysis
stocks
This ASX miner is the cheapest in our iron ore coverage
stocks
Apple names new CEO as Tim Cook steps aside after 15 years
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,074.40 | 50.80 | -0.56% |
| CAC 40 | 8,209.65 | 26.06 | -0.32% |
| DAX 40 | 24,223.33 | 47.54 | -0.20% |
| Dow JONES (US) | 49,149.38 | 293.18 | -0.59% |
| FTSE 100 | 10,492.30 | 5.79 | -0.06% |
| HKSE | 26,163.24 | 324.24 | -1.22% |
| NASDAQ | 24,259.96 | 144.43 | -0.59% |
| Nikkei 225 | 59,585.86 | 236.69 | 0.40% |
| NZX 50 Index | 12,945.60 | 13.27 | 0.10% |
| S&P 500 | 7,064.01 | 45.13 | -0.63% |
| S&P/ASX 200 | 8,843.60 | 53.20 | -0.60% |
| SSE Composite Index | 4,106.26 | 21.18 | 0.52% |